| Literature DB >> 32276153 |
Sonia Ahmed1, Gail R Goldberg2, Rubhana Raqib3, Swapan Kumar Roy3, Shahidul Haque4, Vickie S Braithwaite5, John M Pettifor6, Ann Prentice2.
Abstract
OBJECTIVES: A high prevalence of rickets of unknown aetiology has been reported in Chakaria, Bangladesh. Classically, rickets is caused by vitamin D deficiency but increasing evidence from Africa and Asia points towards other nutritional deficiencies or excessive exposure to some metals. The aim of this study was to investigate the aetiology of rickets in rural Bangladeshi children.Entities:
Keywords: Bangladesh; Calcium; Fibroblast growth factor 23; Phosphate; Rickets; Vitamin D
Mesh:
Substances:
Year: 2020 PMID: 32276153 PMCID: PMC7262584 DOI: 10.1016/j.bone.2020.115357
Source DB: PubMed Journal: Bone ISSN: 1873-2763 Impact factor: 4.398
Age and anthropometry of the participants by group.
| Variable | Group A | Group B | ||||
|---|---|---|---|---|---|---|
| Cases | Controls | Cases | Controls | |||
| Age (y) | 2.7 (2.1, 3.4) | 3.2 (2.5, 4.3) | 0.04 | 3.0 (1.9, 4.3) | 3.2 (2.4, 5.1) | 0.0006 |
| Weight (kg) | 9.7 (1.7) | 11.6 (2.6) | 0.004 | 11.4 (2.7) | 12.9 (3.9) | 0.05 |
| Height (cm) | 78.8 (7.4) | 90.4 (9.6) | ≤0.0001 | 86.7 (10.1) | 94.4 (14.3) | 0.008 |
| Weight for age | −2.99 (1.10) | −2.11 (1.13) | 0.006 | −2.28 (1.01) | −1.88 (1.20) | 0.1 |
| Height for age Z-score | −4.18 (1.50) | −1.90 (1.21) | ≤0.0001 | −2.67 (1.77) | −1.71 (1.44) | 0.003 |
| Sitting height (cm) | 46.8 (3.6) | 53.5 (7.1) | 0.0003 | 50.2 (5.1) | 54.5 (6.8) | 0.0002 |
| Demispan (cm) | 36.9 (4.0) | 42.4 (5.8) | 0.002 | 40.3 (4.8) | 43.5 (6.4) | 0.05 |
| MUAC (mm) | 140 (7) | 147 (11) | 0.05 | 145 (11) | 148.0 (11) | 0.7 |
Data are described by mean (standard deviation) except age median (25th centile, 75th centile).
Group A: active rickets, Group B: rickets-like bone deformities, MUAC: mid-upper arm circumference. p-value indicates the significance of difference between cases and their linked controls in Groups A and B.
Calculated from WHO growth standards.
Dietary calcium, phosphorus and energy intakes of the participants by group.
| Variable | Group A | Group B | ||||
|---|---|---|---|---|---|---|
| Cases | Controls | Cases | Controls | |||
| Calcium mg/d | 156 (80) | 323 (249) | 0.005 | 239 (166) | 254 (222) | 0.7 |
| Phosphorus mg/d | 322 (113) | 424 (155) | 0.009 | 380 (158) | 403 (168) | 0.3 |
| Ca:P (mg/mg) | 0.49 (0.23) | 0.74 (0.53) | 0.03 | 0.64 (0.37) | 0.61 (0.34) | 0.7 |
| Energy Kcal/day | 847 (197) | 961 (314) | 0.05 | 905 (388) | 992 (358) | 0.2 |
| Calcium/energy | 185 (86) | 345 (266) | 0.007 | 288 (203) | 249 (160) | 0.4 |
| Phosphorus/energy | 378 (74) | 446 (103) | 0.02 | 427 (88) | 405 (77) | 0.2 |
Normally distributed data, the results are mean (SD). Group A: active rickets, Group B: rickets-like bone deformities. Paired t-tests were used to calculate p-values for differences between cases and controls in Groups A and B.
Calcium/energy and phosphorus/energy = calculated values for calcium and phosphorus intakes in mg/1000 kcal of energy intake.
Blood biochemistry of the participants by group.
| Variable | Group A | Group B | ||||
|---|---|---|---|---|---|---|
| Cases | Controls | Cases | Controls | |||
| TALP (U/L)* | 595 (372, 953) | 234 (172, 318) | ≤0.0001 | 265 (186, 379) | 214 (147, 313) | 0.02 |
| BALP (μg/L)* | 265 (156, 450) | 81 (52, 125) | ≤0.0001 | 93 (58,151) | 75 (54, 106) | 0.03 |
| PTH (ng/L)* | 158.7 (53.0, 475.0) | 44.0 (24.2, 80.0) | ≤0.0001 | 50.9 (24.3, 106.8) | 27.7 (10.2, 74.7) | 0.002 |
| 1,25(OH)2D (pmol/L)* | 479 (356, 646) | 288 (214, 389) | ≤0.0001 | 363 (249, 529) | 311 (229, 423) | 0.05 |
| 25OHD (nmol/L) | 23.7 (7.87) | 44.9 (12.0) | ≤0.0001 | 42.8 (18.9) | 48.6 (16.5) | 0.2 |
| pCa (mmol/L)* | 1.90 (1.59, 2.27) | 2.07 (1.84, 2.34) | 0.004 | 2.13 (1.89, 2.41) | 2.18 (1.97, 2.41) | 0.9 |
| pPhos (mmol/L)* | 1.16 (0.87, 1.55) | 1.62 (1.37, 1.90) | ≤0.0001 | 1.64 (1.35, 2.00) | 1.63 (1.40, 1.89) | 0.7 |
| pMg(mmol/L)* | 0.85 (0.74, 0.98) | 0.85 (0.75, 0.97) | 0.9 | 0.91 (0.78, 1.06) | 0.89 (0.78, 1.01) | 0.3 |
| pZn (μmol/L)* | 12.4 (10.5, 130.6) | 11.6 (9.94, 115.0) | 0.2 | 13.1 (10.8, 142.0) | 12.2 (10.1, 123.0) | 0.7 |
| pCr (μmol/L)* | 14.5 (10.4, 20.2) | 19.8 (13.6, 28.9) | 0.006 | 19.6 (13.7, 27.9) | 20.8 (15.5, 27.7) | 0.4 |
| Albumin (g/L) | 40.5 (6.61) | 39.4 (6.38) | 0.4 | 40.9 (5.79) | 40.1 (4.76) | 0.4 |
| iFGF23 (pg/mL)§ | 2.5 (2.5, 2.5) | 22.2 (16.5, 26.9) | ≤0.0001 | 18.9 (5.5, 29.0) | 24.5 (14.8, 30.7) | 0.4 |
| cFGF23 (RU/mL)* | 34.2 (15.7, 74.5) | 41.8 (22.8, 76.6) | 0.3 | 44.4 (22.5, 87.3) | 45.2 (24.9, 82.2) | 0.9 |
| Hb (g/L) | 102 (8.4) | 102 (8.0) | 0.9 | 103 (6.8) | 103 (9.0) | 0.8 |
| Ferritin (μg/L)* | 33.0 (19.2, 56.6) | 27.7 (16.8, 45.7) | 0.3 | 32.8(15.5, 69.4) | 31.3(16.2, 60.3) | 0.7 |
| sTfR (mg/L)* | 5.46 (4.48, 6.66) | 5.17 (4.03, 6.63) | 0.4 | 5.30 (3.97, 7.07) | 4.69 (3.74, 5.88) | 0.03 |
| CRP (mg/L)* | 2.22 (0.87, 5.67) | 2.07 (1.16, 3.68) | 0.5 | 2.20 (1.25, 3.87) | 2.02 (1.24, 3.29) | 0.6 |
| AGP (g/L)* | 0.67 (0.45, 1.00) | 0.76 (0.53, 1.09) | 0.2 | 0.82 (0.57,1.18) | 0.75 (0.49, 1.14) | 0.1 |
| Bilirubin (μmol/L)* | 2.86 (2.21, 3.69) | 3.27 (2.37, 4.52) | 0.1 | 3.28 (2.36, 4.55) | 3.49 (2.34, 5.20) | 0.5 |
| AST (U/L)* | 38.3 (29.3, 50.0) | 38.1 (27.9, 51.9) | 0.9 | 38.4 (30.5, 48.3) | 33.9 (22.1, 51.9) | 0.07 |
For normally distributed data, the results are mean (standard deviation); for positively skewed data (denoted by *) the results are geometric mean (geometric mean-1SD, geometric mean + 1SD); for iFGF23 (denoted by §) with substantial proportion below the level of detection of the assay (given a nominal value of 2.5 pg/mL) the results are median (25th centile, 75th centile). Group A: active rickets, Group B: rickets-like bone deformities. TALP and BALP: Total and bone specific alkaline phosphatase respectively, PTH: Parathyroid hormone, 1,25(OH)2D: 1,25-dihydroxyvitamin D, 25OHD: 25-hydroxyvitamin D, pCa: Calcium; pPhos: Phosphate, pMg: Magnesium, pZn: Zinc, pCr: Creatinine, cFGF23 and iFGF23: c-terminal and intact- fibroblast growth factor respectively, Hb: Haemoglobin, sTfR: Serum transferrin receptor, CRP: C-reactive protein, AGP: α1-acid glycoprotein and AST: aspartate transaminase. Paired t-tests were used to calculate p-values for differences between cases and controls in Groups A and B with variables transformed to natural logarithms, except for iFGF23 for which the non-parametric paired sign test was used.
Percentage of participants with blood values above or below accepted norms or the presence of H. pylori infection by group.
| Variable | Group A | Group B | ||||
|---|---|---|---|---|---|---|
| Threshold used for status | Cases | Controls | Cases | Controls | ||
| TALP (%) High: ≥300 U/mL | 92 | 17 | ≤0.0001 | 42 | 16 | 0.01 |
| TALP (%) Severe: ≥960 U/mL | 8 | 0 | 0.2 | 0 | 0 | – |
| PTH (%) High: >58 ng/L | 88 | 25 | ≤0.0001 | 42 | 26 | 0.2 |
| 25OHD (%) Low: <25 nmol/L | 63 | 8 | ≤0.0001 | 13 | 5 | 0.2 |
| 25OHD (%) Severe <12.5 nmol/L | 4 | 0 | 0.3 | 0 | 0 | – |
| pCa (%) Low: ≤2.25 mmol/L | 91 | 88 | 0.9 | 72 | 75 | 0.6 |
| pPhos (%) Low: ≤1.45 or ≤1.20 mmol/La | 83 | 22 | ≤0.0001 | 16 | 14 | 0.8 |
| iFGF23 (%) Low: <5 pg/mL | 88 | 4 | ≤0.0001 | 21 | 0 | 0.006 |
| iFGF23 (%) High: ≥51.9 pg/mL | 0 | 0 | – | 0 | 0 | – |
| cFGF23 (%) High: >125 RU/mL | 4 | 8 | 0.6 | 8 | 3 | 0.3 |
| Hb (%) Low: <110 or <115 g/La | 67 | 71 | 0.8 | 76 | 74 | 0.8 |
| Ferritin (%) Low: ≤10 or ≤15 μg/La | 4 | 8 | 0.6 | 5 | 8 | 0.6 |
| CRP (%) High: ≥5 mg/L | 15 | 7 | 0.5 | 11 | 5 | 0.4 |
| Iron deficiency anaemia (%) | 8 | 17 | 0.4 | 18 | 21 | 0.8 |
| 29 | 58 | 0.04 | 49 | 51 | 0.5 | |
Group A: active rickets, Group B: rickets-like bone deformities. McNemar ϰ2 test p-values are presented. aThreshold values for <5 and >5 year old children. TALP: Total alkaline phosphatase, PTH: Parathyroid hormone, 25OHD: 25-hydroxyvitamin D, pCa: Calcium; pPhos: Phosphate, iFGF23 and cFGF23: intact- and c-terminal fibroblast growth factor, Hb: Haemoglobin, sTfR: Serum transferrin receptor, CRP: C-reactive protein, Iron Deficiency Anaemia: Low haemoglobin plus microcytic and hypochromic red blood cells.
Urinary excretion of bone-forming minerals of the participants by group.
| Variable | Group A | Group B | ||||
|---|---|---|---|---|---|---|
| Cases | Controls | Cases | Controls | |||
| 0.67 (0.21, 2.15) | 0.62 (0.24, 1.64) | 0.6 | 0.61 (0.18, 2.08) | 0.71 (0.27, 1.83) | 0.6 | |
| uPhos:Cr mol/mol* | 5.52 (3.50, 8.69) | 3.73 (2.31, 6.01) | 0.009 | 4.79 (2.28, 10.1) | 3.60 (1.92, 6.77) | 0.04 |
| uMg:Cr (mol/mol)* | 0.83 (0.46, 1.50) | 0.47 (0.20, 1.13) | 0.1 | 0.68 (0.36, 1.29) | 0.46 (0.19, 1.08) | 0.3 |
| TmCa/GFR mmol/L | 1.96 (0.46) | 2.13 (0.45) | 0.02 | 1.93 (0.45) | 1.87 (0.42) | 0.08 |
| TmP/GFR mmol/L | 1.20 (0.36) | 1.92 (0.39) | ≤0.0001 | 1.88 (0.48) | 1.96 (0.46) | 0.3 |
| 0.036 (0.017, 0.077) | 0.055 (0.025, 0.119) | 0.009 | 0.059 (0.018, 0.194) | 0.075 (0.302,0.187) | 0.4 | |
| Ccr mL/min* | 21.3 (8.72, 52.2) | 23.0 (9.60, 55.1) | 0.6 | 25.2 (7.48, 84.9) | 29.9(11.8, 75.7) | 0.6 |
| uCa mmol/24 h | 0.15 (0.06, 0.36) | 0.31 (0.14, 0.66) | ≤0.0001 | 0.29 (0.13, 0.64) | 0.41 (0.18, 0.94) | 0.02 |
| uPhos mmol/24 h | 2.56 (1.29, 5.08) | 2.93 (1.41, 6.11) | 0.5 | 3.17 (1.83, 5.49) | 3.41 (1.88, 6.19) | 0.5 |
| uMg mmol/24 h | 0.58 (0.29, 1.15) | 0.81 (0.41, 1.59) | 0.08 | 0.78 (0.41, 1.49) | 0.86 (0.46, 1.61) | 0.3 |
| uCr mmol/24 h* | 0.51 (0.27, 0.96) | 0.87 (0.48, 1.58) | 0.001 | 0.75 (0.46, 1.22) | 0.96 (0.53, 1.75) | 0.008 |
| uCa:Cr (mol/mol)* | 0.29 (0.13, 0.69) | 0.35 (0.17, 0.75) | 0.2 | 0.39(0.19, 0.81) | 0.42 (0.20, 0.89) | 0.6 |
| uPhos:Cr (mol/mol)* | 5.00 (3.73, 6.72) | 3.36 (2.35, 4.81) | ≤0.0001 | 4.22 (3.13, 5.69) | 3.54 (2.52, 4.97) | 0.02 |
| uMg/Cr (mol/mol) | 1.13 (0.69, 1.84) | 0.93 (0.60, 1.83) | 0.1 | 1.04 (0.66, 1.64) | 0.89 (0.53, 1.50) | 0.1 |
| Ccr mL/min* | 24.0 (11.4, 50.4) | 30.5 (15.3, 60.8) | 0.2 | 26.6 (16.2, 43.6) | 32.3 (18.7, 55.6) | 0.05 |
| uVolume (mL/24 h) | 436 (252) | 496 (212) | 0.2 | 497 (264) | 595 (342) | 0.06 |
For normally distributed data, the results are mean (standard deviation); for positively skewed data (denoted by *) the results are geometric mean (geometric mean-1SD, geometric mean + 1SD). Group A: active rickets, Group B: rickets-like bone deformities, u: urinary, Ca: Calcium, Phos: Phosphate, Mg: Magnesium, Cr: Creatinine, TmCa/GFR and TmP/GFR: Tubular maximum calcium or phosphate reabsorption per unit of glomerular filtrate rate respectively, Ccr: Creatinine clearance. Paired t-tests were used to calculate p-values for differences between cases and controls in Groups A and B with variables transformed to natural logarithms.